Press releases - GSK
WEBGSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer.
Press releases - GSK US
WEBGSK announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the safety of AREXVY and SHINGRIX. GSK confirmed it has reached two …
GSK announces cap of $35 per month on U.S. patient out-of …
WEBGSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines,* the most prescribed portfolio of inhalers in the U.S. GSK is taking this action as part of its longstanding commitment to improving access to respiratory medici...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK's experimental drug shows promise in reducing severe …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker expects to...
FDA Approves GSK's New Blood Cancer Treatment - Bloomberg
WEBSep 15, 2023 · The US Food and Drug Administration cleared a new treatment from GlaxoSmithKline Plc for a rare blood cancer, bolstering the UK pharmaceutical company’s push back into oncology.
GSK lifts annual forecasts again, powered by strong vaccine launch
WEBNov 1 (Reuters) - GSK (GSK.L) raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its respiratory syncytial virus (RSV) vaccine in the...
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
WEBLONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory...
GSK to acquire clinical-stage biopharmaceutical company …
WEBMay 31, 2022 · GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones. Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology.
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.